Published in J Transl Med on June 07, 2010
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology (2012) 0.93
DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother (2015) 0.89
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res (2014) 0.89
Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. Cancer Res (2014) 0.88
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87
The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med (2012) 0.86
Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol (2013) 0.86
Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) (2014) 0.85
Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Front Oncol (2013) 0.81
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers (Basel) (2011) 0.80
Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep (2014) 0.79
Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother (2012) 0.77
Evolution of animal models in cancer vaccine development. Vaccine (2015) 0.77
Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet (2014) 0.77
Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunol Res (2015) 0.76
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol (2003) 2.34
DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med (1996) 2.18
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2006) 1.95
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res (1999) 1.68
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
DNA vaccines. Life Sci (1997) 1.53
DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res (1998) 1.53
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res (2000) 1.43
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res (2009) 1.38
Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer (1999) 1.33
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res (2008) 1.33
Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res (2002) 1.28
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res (2004) 1.26
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol (2006) 1.24
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol (2004) 1.19
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med (2007) 1.11
Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther (2004) 1.08
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell (2007) 1.06
Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol (2005) 1.06
Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res (2002) 1.05
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun (2006) 1.04
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol (2004) 1.04
ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol (2008) 1.00
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother (2008) 1.00
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol (2009) 1.00
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer (2000) 1.00
Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol (1993) 0.97
NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Mol Cell Endocrinol (1994) 0.94
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer (2004) 0.90
The "A, B and C" of Her-2 DNA vaccine development. Cancer Immunol Immunother (2008) 0.85
A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol (1999) 0.83
A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res (2010) 0.82
DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum Gene Ther (2001) 0.81
Novel agents in the era of targeted therapy: what have we learned and how has our practice changed? Ann Oncol (2008) 0.79
Is trastuzumab associated with adverse cardiac effects in patients with breast cancer? Nat Clin Pract Oncol (2008) 0.77
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Heat-shock proteins as activators of the innate immune system. Trends Immunol (2002) 2.96
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A (2008) 2.64
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens (2002) 2.05
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res (2006) 2.02
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol (2012) 2.00
Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood (2008) 1.96
Low concordance of biomarkers in histopathological and cytological material from breast cancer. Histopathology (2014) 1.96
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics (2005) 1.86
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol (2009) 1.81
Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol (2007) 1.68
Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res (2011) 1.67
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol (2005) 1.66
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. 1986. J Immunol (2005) 1.64
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat (2009) 1.60
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 1.60
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol (2006) 1.52
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother (2011) 1.44
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast (2009) 1.42
Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol (2009) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother (2011) 1.36
On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol (2012) 1.35
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat (2010) 1.31
Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res (2011) 1.30
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood (2011) 1.24
Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol (2005) 1.22
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A (2006) 1.22
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood (2007) 1.21
Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat (2010) 1.20
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol (2004) 1.19
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res (2003) 1.19
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res (2002) 1.18
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res (2002) 1.17
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol (2003) 1.17
Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol (2007) 1.16
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancer. Acta Oncol (2006) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Designer T cells by T cell receptor replacement. Eur J Immunol (2006) 1.14
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2010) 1.14
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat (2010) 1.13
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem (2004) 1.13
Is survivin the potential Achilles' heel of cancer? Adv Cancer Res (2011) 1.12
Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res (2007) 1.11